Evidence map›Paper›PMID 35646227›Full record

ArticleKidney cancer journal : official journal of the Kidney Cancer Association2022

The Latinx Disparity in Surgery for Kidney Cancer: Data from The South Texas Region.

Furkan Dursun, Rahul S Patel, Dawn Hui, Hanzhang Wang, Ahmed Mansour, Deepak Pruthi, David G Alonso, Lalithapriya Jayakumar, Ronald Rodriguez, Robert S Svatek and 2 more

Abstract read
In one paragraph

Article in Kidney cancer journal : official journal of the Kidney Cancer Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Patency outcomes of primary inferior vena cava repair in radical nephrectomy and tumor thrombectomy.Journal of vascular surgery. Venous and lymphatic disorders · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Furkan DursunDepartment of Urology, University of Texas Health San Antonio, TX, USA.
Rahul S PatelDepartment of Urology, University of Texas Health San Antonio, TX, USA.
Dawn HuiDepartment of Cardiothoracic Surgery, University of Texas Health San Antonio, TX, USA.
Hanzhang WangDepartment of Urology, University of Texas Health San Antonio, TX, USA.
Ahmed MansourDepartment of Urology, University of Texas Health San Antonio, TX, USA.
Deepak PruthiDepartment of Urology, University of Texas Health San Antonio, TX, USA.
David G AlonsoDepartment of Urology, University of Texas Rio Grande Valley, TX, USA.
Lalithapriya JayakumarDepartment of Surgery, Division of Vascular & Endovascular Surgery, University of Texas Health San Antonio, TX, USA.
Ronald RodriguezDepartment of Urology, University of Texas Health San Antonio, TX, USA.
Robert S SvatekDepartment of Urology, University of Texas Health San Antonio, TX, USA.
Michael A LissDepartment of Urology, University of Texas Health San Antonio, TX, USA.
Dharam KaushikDepartment of Urology, University of Texas Health San Antonio, TX, USA.

Funding

eRapa for bladder cancer preventionR01CA252057 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SVATEK, ROBERT SCOTT · 2020 to 2024
$2.3M
Improving immunotherapy in bladder cancer by targeting immune dysfunctionK23CA178204 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI SVATEK, ROBERT SCOTT · 2014 to 2017
$674k
NCI NIH HHS K23 CA178204NCI NIH HHS R01 CA252057
6 · The paper itself

Abstract

The South Texas region, with a predominantly Latinx population, has a very high incidence of renal cell carcinoma (RCC), including those with tumor extending into the major blood vessels called venous tumor thrombus (VTT). There is currently no data on outcomes of Latinx patients with VTT as most published studies are from predominantly Caucasian population. Therefore, we performed this study to fill an urgent, unmet need. We reviewed patients who underwent radical nephrectomy with removal of VTT (called tumor thrombectomy) between 2015 and 2020. We collected data on demographics, clinical, pathological characteristics and outcomes of patients. Univariate and multivariate Cox regression analyses were used to evaluate the associations between ethnicity and disease progression or survival. We identified 112 patients, of which 67 (62%) were Latinx, and 41 (38%) were non-Latinx. Approximately 60% of patients had Level II-IV VTT; Latinx presented with a higher level of tumor thrombus (p=0.046). Latinx patients had a higher rate of no insurance (11% vs. 27%, p=0.04) and were more likely to lost to follow-up after surgery (22.4% vs. 13.3%, p=0.23) compared to non-Latinx. Fewer Latinx received systemic therapy (28% vs. 42%; p=0.13). Ninety-day mortality for the entire cohort was 3.8%. The Latinx population in the South Texas region present late, with advanced thrombus level, and do not have access to systemic therapy. Given symptomatic disease, surgical treatment, if feasible, is their only option. Our results highlight disparate treatment patterns which require further investigation and health-care policy changes.

Indexed as

LatinxRenal cell carcinomaTumor thrombectomyVenous tumor thrombus

Identifiers

PMID35646227
PMCPMC9137392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.